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Neutropenic sepsis remains a potentially life-threatening complication of anticancer chemotherapy. However, it is possible to identify
patients who are at low risk for serious complications and for whom less-intensive, more-convenient treatment may be appropriate.
The aim of this study was to assess the efficacy and safety of oral antibiotics in conjunction with early hospital discharge in comparison
with standard in-patient intravenous antibiotics in patients with low-risk neutropenic fever. In all, 126 episodes of low-risk neutropenic
fever occurred in 102 patients. Patients were randomised to receive either: an oral regimen of ciprofloxacin (750mg 12hourly) plus
amoxicillin–clavulanate (675mg 8hourly) for a total of 5 days, or a standard intravenous regimen of gentamicin and tazocin
(piperacillin/tazobactam) until hospital discharge. Patients randomised to oral antibiotics were eligible for discharge following 24h of
hospitalisation, if clinically stable and symptomatically improved. The efficacy of the two arms was similar: initial treatment was
successful without antibiotic modification in 90% of episodes in the intravenous arm and 84.8% of episodes in the oral arm, P¼0.55,
absolute difference between the groups 5.2%; 95% confidence interval (CI) for the difference  7 to 17.3%. Only one episode in the
oral arm was associated with significant clinical deterioration: this occurred within the initial in-patient assessment period. The median
in-patient stay was 4 days in the intravenous arm (range 2–8) and 2 days in the oral arm (range 1–16 days), Po0.0005. The
reduction in hospital stay led to significant cost-savings in the oral arm. In conclusion, this study suggests that oral antibiotics in
conjunction with early hospital discharge for patients who remain stable after a 24h period of in-patient monitoring offers a feasible
and cost-effective alternative to conventional management of low-risk neutropenic fever.
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Neutropenic sepsis is a well recognised, potentially life-threatening
complication for patients undergoing cytotoxic chemotherapy for
cancer (Bodey et al, 1966). As a consequence, prompt in-patient
therapy with broad-spectrum intravenous antibiotics has become
the standard of care for all patients who develop febrile episodes
while neutropenic (Hughes et al, 1990, 1997). While this approach
has undoubtedly reduced mortality from sepsis, it has become
increasingly recognised that febrile neutropenia represents a
spectrum of potential severity and that only a relatively small
proportion of patients are at high risk of complications or death,
the great majority of febrile episodes running a benign course.
Several groups of investigators have independently developed
prognostic indices in neutropenic fever, in an attempt to identify
criteria by which to define ‘low-risk’ (Rubin et al, 1988; Talcott
et al, 1988, 1992; Viscoli et al, 1994; Elting et al, 1997). More
recently, these groups have come together in an international
collaboration with the publication of a ‘risk index’ (Klastersky et al,
2000) using a weighted scoring system of clinical factors, based
upon analysis of 1139 episodes of neutropenia.
The aim of defining low-risk neutropenia has been to identify
those patients who may be candidates for less-intensive,
more-convenient antibiotic therapy. Thus, in parallel with the
development of the definition of low-risk, several studies have
demonstrated the feasibility of newer approaches including
intravenous antibiotic monotherapy (Pizzo et al, 1986; Sanders
et al, 1991; Rolston et al, 1992; Marshall et al, 2000), outpatient
ambulatory intravenous therapy (Rubenstein et al, 1993; Talcott
et al, 1994) and the use of oral antibiotic regimens (Gardembas-
Pain et al, 1991; Malik et al, 1992). These approaches have recently
culminated in the publication of two large prospective randomised
trials (Freifeld et al, 1999; Kern et al, 1999) that have reported
equivalence in terms of both efficacy and safety for an in-patient
combination oral antibiotic regimen as compared with standard
in-patient parenteral regimen. However, the general applicability
of oral therapy has been challenged in view of the relatively high
levels of gastrointestinal toxicity of the oral regimen and the high
rates of use of colony-stimulating factors (CSFs) in these study
populations.
Oral antibiotic therapy has been evaluated in the outpatient
setting by a number of groups but with variable findings. Malik
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let al (1995) compared outpatient oral antibiotic treatment with in-
patient oral antibiotic treatment in an unselected group of cancer
patients, including patients with acute leukaemia. Efficacy in the
two groups was similar; however, 21% of the patients allocated to
the outpatient group required hospitalisation and the study
reported a 4% mortality rate, raising some concerns about the
safety of this approach.
Serial studies at the MD Anderson Center (Rubenstein et al,
1993; Elting et al, 1997) using both intravenous and oral regimens
in the outpatient setting have reported both high response rates
and low readmission rates. However, these studies have not
evaluated outpatient therapy in a randomised comparison with
standard in-patient intravenous treatment.
Based on our own experience of managing low-risk neutropenic
fever (Marshall et al, 2000), we initiated a single-centre rando-
mised trial comparing a combination oral antibiotic regimen of
ciprofloxacin and amoxicillin-clavulanate with early hospital
discharge vs conventional in-patient management using a standard
combination of intravenous antibiotics. The primary objectives of
this study were to assess the efficacy and safety of this approach.
Secondary objectives included duration of hospitalisation, re-
admission rates, patient acceptability and resource utilisation.
PATIENTS AND METHODS
Patient eligibility
Patients were recruited from Clatterbridge Centre for Oncology, a
regional cancer facility treating solid tumours and lymphomas
serving a population of 2 million people in Merseyside, UK.
Patients undergoing conventional dose cytotoxic chemotherapy
(i.e., nonmyeloablative chemotherapy not requiring routine use of
growth factors given according to the internationally accepted
protocols) were recruited between February 1997 and September
2000.
Neutropenia was defined according to standard criteria
(Hughes et al, 1990, 1997) as an absolute neutrophil count
(ANC) p0.5 10
9l
 1, but patients were also eligible if their
ANC was p1 109l
 1, but anticipated to fall to p0.5 10
9l
 1
within 24h of entry into the study. Fever was defined as a
temperature of X38
oC on two oral measurements 4h apart
within a 24h period, one of which could have been measured
by the patient prior to admission, or X38.5
oC on one occasion.
It was also required that patients should have an anticipated
duration of neutropenia of no longer than 7 days. Patients could be
entered more than once following subsequent episodes of febrile
neutropenia.
Patients were required to be haemodynamically stable with no
signs or symptoms that required intravenous fluid support.
Adequate renal function and the ability to maintain satisfactory
oral intake were therefore required.
Patients were not eligible if they had undergone autologous bone
marrow or peripheral blood stem-cell transplantation or had
received antibacterial medication within 7 days of enrolment. The
use of CSFs and cytokines was not permitted.
Further exclusion criteria included (i) any coexisting medical
condition that would require in-patient treatment or monitoring,
(ii) clinically documented infection, in the opinion of the
investigator, likely to require targeted or prolonged duration of
antibiotic therapy (e.g. cellulitis, abscess, pneumonia, CVC tunnel
infection), (iii) inability to tolerate oral medication, and (iv)
known allergy to study drugs.
Finally, all patients were required to have a responsible adult
living with them who would be prepared to act as a carer if the
patient were eligible for early discharge. Either patient or carer was
also required to be able to read a thermometre. Patients with a
history of poor compliance were excluded. All patients were 18 or
over and gave written informed consent.
Randomisation
All patients were initially assessed with a history and full physical
examination. Standard screening investigations consisted of a full
blood count and differential, a biochemical screen and a minimum
of one set of peripheral venous blood cultures in addition to
cultures via a central venous catheter if present. Chest radiographs
and other microbiological cultures were performed only where
clinically indicated.
Eligible patients were randomly assigned by means of consecu-
tively drawn sealed envelopes to receive either an oral regimen of
ciprofloxacin 750mg every 12h plus amoxicillin–clavulanate
(amoxicillin 500mgþclavulanate 175mg) every 8h for a total of
5 days, or an intravenous regimen of gentamicin 80mg every 8h
and dose adjusted according to therapeutic levels plus tazocin
(piperacillin 4gþtazobactam 500mg; Lederle, Maidenhead, UK)
every 8h until hospital discharge.
Assessment and monitoring
Patients randomised to the intravenous arm were subject to a
standard protocol for the management of neutopenic fever, with
daily clinical assessment, repeat full blood count and differential at
48h intervals, repeat blood cultures for patients with persistent
fever and any additional investigations as clinically indicated.
Patients were eligible for discharge when afebrile for 24h with a
rising neutrophil count (irrespective of the absolute value).
Patients did not routinely receive antibiotics on discharge.
Indications for changes in the treatment regimen included
persistent fever X72h, positive culture results with resistant
organisms, or clinical deterioration at the discretion of the treating
clinician.
Patients randomised to the oral arm were eligible for discharge
following 24h of hospitalisation, if clinically stable and sympto-
matically improved, and according to the patient’s wishes. On
discharge, patients were supplied with a daily diary to record their
temperature at 6-hourly intervals and any associated symptoms,
and telephone contact was maintained with a member of the
clinical research team. They were also given oral and written
instructions with a 24-h contact telephone number at the specialist
centre, emphasising the need for early reporting of any sympto-
matic deterioration. After discharge, patients were reviewed 7–10
days later in the oncology outpatient department to ensure full
haematological recovery, assess outcome and determine further
oncological management.
Those patients randomised into the oral arm who were not
discharged after the 24h assessment were reassessed daily
including their eligibility for discharge as described above. Criteria
for alterations to the antibiotic regimen were as outlined in the
intravenous arm together with the inability to tolerate oral
medication for any reason. Patients in the oral arm who required
readmission following early discharge had their antibiotic regimen
altered at the discretion of the treating physician depending on the
indication for readmission.
Definition and assessment of study end points
The primary end points of the study were success and safety.
‘Success’ was defined according to EORTC guidelines (Cometta
et al, 1995) as lysis of fever and resolution of symptoms and signs
with no modifications to the initial antibiotic regimen and with no
recurrence within 7 days. Safety was assessed by the frequency of
serious medical complications and deaths.
Secondary end points were total duration of hospital admission,
frequency of readmission, toxicity of treatment and resource
utilisation. Toxicity of treatment was assessed according to the
Common Toxicity Criteria of the National Cancer Institute.
Patients in the oral arm who had been discharged before
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for self-completion.
Resource utilisation was assessed by comparing the financial
costs of neutropenic episodes and the nursing care required for
episodes of neutropenic fever in both arms. Estimated hospitalisa-
tion costs were calculated using a mean cost per routine in-patient
day as determined by previous studies (Leese, 1993) (including
medical, nursing, paramedical services and supplies, and general
services such as catering and laundering, but excluding pharmacy
and pathology costs to exclude double counting) multiplied by the
number of in-patient days (including days after readmission where
appropriate). Antibiotic costs were calculated according to
standard NHS charges. Costs incurred by diagnostic tests and
other therapeutic interventions were assumed to be equivalent in
both arms and hence were excluded from the calculations.
A comparison of nursing resources was made using ‘GRASP’
(GRASP Systems Nurse Consulting International, CO, USA), an
international nursing workload management system that is
increasingly used within the NHS, to obtain an estimate of the
nursing time required in ‘actual patient contact’.
Statistics
From our own previous experience and previously published
studies, and assuming a response rate of approximately 80% for
the intravenous arm, this study was designed to enrol 63 episodes
per arm to ensure that the oral arm would not be 20% worse (i.e.
60%, equivalent) at a level of significance a¼0.05 with power of
80% using a two-sided w
2 test (N Query sample size program). In
addition, first episodes of neutropenic fever (i.e. occurring in
patients not previously randomised) were analysed separately
to exclude any bias induced by repeat randomisation. We used
the w
2 test or Fisher’s exact test to compare various base-
line characteristics and outcomes between the groups. The
Mann–Whitney U-test was used to compare the continuous
variables of neutrophil counts and stay length.
RESULTS
Patient characteristics
Between February 1997 and August 2000 111 patients, representing
135 episodes of fever associated with neutropenia, consented to
participate in the study. Of the 135 episodes evaluated, nine
episodes were excluded from the analysis, seven in the intravenous
arm and two in the oral arm. Eight failed to meet the inclusion
criteria; four were not neutropenic, one did not have fever, one
required intravenous fluids at the time of randomisation, one had
received antibiotics within 7 days of being entered into the study
and one was allergic to study drugs. The final patient withdrew
consent prior to commencement of antibiotics. The remaining 126
eligible episodes occurred in 102 patients (87 patients randomised
once, 10 twice, three three times, one four times and one six times).
Sixty eligible episodes of neutropenic fever were assigned to the
intravenous regimen of gentamicin and tazocin and 66 were
assigned to receive the oral regimen of ciprofloxacin and
amoxicillin–clavulanate. Of the 102 first episodes of neutropenic
fever (i.e. occurring in patients not previously randomised), 51
were in the oral and 51 in the intravenous arm. The arms were well
balanced with respect to age, sex and primary site of cancer,
Table 1.
The majority of episodes occurred in women, reflecting the most
frequent underlying diagnoses of breast cancer and small-cell lung
cancer. Only 4.8% of episodes had a diagnosis of lymphoma, 92%
of episodes had neutrophil counts of p0.5 10
9l
 1 at randomisa-
tion.
Clinical symptoms at randomisation were by definition mild to
moderate (CTC grades I–II), Table 1. A total of 36.5% had no
Table 1 Patient characteristics
a
Intravenous arm
(tazocin+gentamicin,
n¼60)
Oral arm
(ciprofloxacin+amoxicillin–
clavulanate,
n¼66)
Age (years)
Median (range) 50 (18–76) 53 (18–78)
Sex
Female, no. (%) 37 (61.7) 41 (62.1)
Diagnosis, no. (%)
Small-cell lung cancer 26 (43.3) 27 (40.9)
Breast 14 (23.3) 22 (33.3)
Testicular 2 (3.3) 3 (4.5)
Lymphoma 2 (3.3) 4 (6.1)
Other 16 (26.7) 10 (15.2)
Neutrophil count at presentation
Median (range) 0.15 (0–0.9) 0.1 (0–0.8)
Neutrophil count p0.5 10
9l
 1
No. (%) 55 (91.7) 61 (92.4)
Symptoms at presentation
Mild–moderate, no. (%)
Mucositis 28 (46.7) 30 (45.5)
Gastrointestinal 4 (6.7) 7 (10.6)
Respiratory 15 (25) 21 (31.8)
Genitourinary 6 (10) 4 (6.1)
No symptoms 23 (38.3) 23 (34.8)
aThere were no significant differences between the two groups.
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lsymptoms other than fever. Positive microbiological cultures are
shown in Table 2. Eight patients had positive microbiological
cultures, of which two were isolated from a single culture and
therefore of questionable significance. Five had documented
clinical infections with positive cultures and the final patient
developed Clostridium difficile associated diarrhoea following
hospitalisation (superinfection).
Efficacy and safety
The success rate to initial antibiotic therapy was similar in both
groups. Treatment was successful in 90% of all episodes of
neutropenic fever in the intravenous arm (95% confidence
intervals 82.4–97.6%) and 84.8% of all episodes of neutropenic
fever in the oral arm, P¼0.55: absolute difference between the
groups is 5.2%; 95% confidence interval for the difference  7t o
17.3%. Treatment was successful in all episodes with positive blood
cultures. The success rates in the 102 first episodes of neutropenic
fever were very similar: 45 of the 51 (88.2%) first episodes of
neutropenic fever in the intravenous arm were successful, while 43
of the 51 (84.3%) first episodes in the oral arm were successful,
P¼0.77.
Episodes of neutropenic fever deemed failures are summarised
in Table 3. In the intravenous arm there was one death. This
patient was undergoing palliative treatment with single agent
doxorubicin for metastatic cystosarcoma phylloides and on
admission had no symptoms of infection other than fever and
no positive bacterial cultures. Both her fever and neutropenia had
resolved prior to discharge. This patient died on the day following
hospital discharge, 3 days following randomisation. The death was
unexpected and was thought to be a consequence of a pulmonary
embolus; however, post-mortem examination was not carried out.
There were no other serious medical complications in the
intravenous arm, and in all other patients there was complete
resolution of the episode of febrile neutropenia without sequelae.
Five episodes required changes to the antibiotic regimen because
of persistent fever, Table 3.
In the oral arm there were no deaths. A total of 10 episodes of
neutropenic fever in the oral arm required modification of the
initial antibiotic regimen and were therefore deemed failures,
Table 3. In only one of these, there was a serious medical
complication: this patient developed hypotension within 12h of
admission. He was given intravenous fluid support and converted
to intravenous antibiotics. Subsequently he developed the symp-
toms and signs of classical lobar pneumonia and required
prolonged in-patient treatment; he was eventually discharged at
16 days after randomisation.
Of the remaining nine failures in the oral arm, all were converted
to intravenous antibiotic regimens. Indications for the modifica-
tion to the initial antibiotic regimen were: intolerance of the oral
regimen due to vomiting (one); development of severe oesopha-
gitis (two) and persistent fever at 72h without serious clinical
deterioration (six).
Five patients in the oral arm required readmission to hospital.
Four of these were deemed failures and are described above. The
fifth patient was readmitted with chest pain diagnosed as a
pulmonary embolism.
Toxicity
Both arms of the study were very well tolerated. In the oral arm
there was one episode (0.8%) of severe toxicity, CTC grade 3, in
which a patient was unable to tolerate oral ciprofloxacin due to
vomiting, thus requiring a change to intravenous antibiotics. Other
toxicity in this arm was mild–moderate gastrointestinal toxicity
that did not require a change in antibiotic regimen, 14 patients
(21.2%) having CTC grade 1–2 diarrhoea and five patients (7.6%)
having CTC grade 1–2 nausea/vomiting. In the intravenous arm,
there were no episodes of toxicity of CTC grade41.
Duration of hospital stay
The median in-patient stay was 4 days in the intravenous arm
(range 2–8) and 2 days in the oral arm (range 1–16 days),
Po0.0005, Table 4. Overall, the oral antibiotic policy resulted in a
reduction of 66 in-patient days (199 compared to 265).
Table 2 Episodes with positive microbiological cultures
Study arm Source Organism Outcome Further detail
Intravenous Peripheral blood culture Pseudomonas aeruginosa Success
Intravenous Peripheral blood culture Coagulase negative staphylococcus
a Success
Oral Peripheral blood culture Anaerobic diphtheroid
b Success
Intravenous Stool Giardia lamblia Failure Patient developed diarrhoea after admission.
Recent travel overseas. Resolution with oral
metronidazole
Intravenous Wound swab Staphylococcus aureus Success
Intravenous Urine Faecal streptococcus Failure Persistent fever despite sensitivity of organism to
study antibiotics. Resolved with addition of
ceftazidime.
Intravenous Stool Clostridium difficile toxin Failure Patient developed diarrhoea after admission,
nosocomial infection. Resolution with oral
metronidazole.
Intravenous Sputum Moraxella catarrhalis Success
aOne positive culture.
bOne positive culture, non-JK group.
Table 3 Reasons for failure of initial antibiotic regimen
Intravenous
arm
Oral
arm
Death 1 0
Serious complication or clinical deterioration
While in-patient 0 1
While outpatient 0 0
Intolerance of antibiotics due to
Vomiting 0 1
Development of severe oesophagitis 0 2
Persistence of fever
With microbiological evidence of resistance 2 0
Without microbiological evidence of resistance 3 6
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The financial costs of hospitalisation and antibiotic costs, together
with the estimated direct patient contact nursing hours required in
the two arms are given in Table 5. Overall the costs of
hospitalisation and antibiotics was more than d19000 less in the
oral arm compared with the intravenous arm, each episode in the
oral arm costing approximately 56% of an episode in the standard
management arm. Similarly, the estimated number of ‘direct
patient care hours’ per episode in the oral arm was less than half of
each episode in the intravenous arm (11 compared with 21).
DISCUSSION
The treatment of neutropenic fever has improved considerably
since its importance as a cause of morbidity and mortality in
cancer patients undergoing chemotherapy was first highlighted
more than 30 years ago (Bodey, 1966). Overall, fewer than 10% of
patients with febrile neutropenia now die as a result of their
infection and it is now possible to identify a subgroup of patients
who are at particularly low risk of developing serious complica-
tions or death (Klastersky et al, 2000). This has in turn led to the
development of less-intensive treatment strategies for low-risk
patients including changes in antimicrobial therapy (combination
vs monotherapy), changes in route of administration (intravenous
vs oral) and treatment setting (in-patient vs outpatient). Response
rates and safety have remained the main end points for antibiotic
research in this area. However, as a consequence of the high
response rates of newer antimicrobials and the low incidence of
complications in this population, the safety and efficacy of
different regimens are very similar (Elting and Cantor, 2002).
Hence, in a manner analogous to the development of cytotoxic
chemotherapy regimens, additional outcome measures need to be
considered to differentiate between treatment strategies. These
may include factors such as time to antibiotic response, total
duration of hospitalisation, readmission rates, toxicity, conveni-
ence, resource utilisation and impact on quality of life.
Here, we present the first study to our knowledge comparing
conventional in-patient treatment with standard intravenous
antibiotics with oral antibiotics in conjunction with early hospital
discharge in patients with low-risk neutropenic fever.
Previous research in this area has been hampered by the lack of
an agreed definition of ‘low-risk’. This has in part been overcome
by the recent introduction of a ‘risk index’ scoring system by the
multinational association for supportive care in cancer (MASCC),
(Klastersky et al, 2000), shown in Table 6. This study preceded the
publication of this risk index, and therefore we have retro-
spectively scored our patients’ baseline characteristics at rando-
misation. While we acknowledge that such retrospective analysis
has limitations, we have found that more than 95% of patients in
this study had scores X21, a threshold which was suggested by the
authors for defining patients at low risk of complications.
The definition of ‘low-risk’ used in the present study was based
on the original definition proposed by Talcott et al (1988).
However, given our intention of early hospital discharge and the
high incidence of complications and readmissions in Talcott’s
initial pilot study of outpatient treatment (Talcott et al, 1994), we
felt that careful patient selection was essential. We therefore
extended the definition to exclude central venous catheter
infections, pneumonia and cellulitis for which the choice of
antibiotic and proposed short duration of antibiotic therapy may
not be appropriate. We also included the previously recognised
criterion of an expected duration of neutropenia of o7 days
(Rubin et al, 1988). Although the anticipated duration of
neutropenia was not found to be predictive of the likelihood of
serious medical complication in the MASCC risk index, it was
predictive of a higher probability of response to empirical
antibiotic therapy without the need for modification, justifying
our inclusion of this factor in our study.
Another important factor in patient selection in this study is that
no patients received haematopoietic CSFs. This is in accordance
with the ASCO 2000 guidelines (Ozer et al, 2000) which
recommend that they should not be routinely used as adjunct
therapy for the treatment of uncomplicated fever and neutropenia.
This is in contrast to the two large randomised studies of oral vs
intravenous antibiotics (Freifeld et al, 1999; Kern et al, 1999) in
which CSFs were administered in 63 and 86% of episodes,
respectively.
Inevitably as a consequence of the strict criteria used to define
‘low-risk’ in this study, the incidence of positive blood and other
cultures was low and the large majority of patients did not have a
defined site of infection. Nevertheless, the appropriate treatment
for this group of patients remains an important clinical question
Table 4 Duration of hospital stay
Intravenous
arm n¼60
Oral arm
n¼66
No. (%) of episodes with in-patient stay length
a
1 day 0 23 (34.8)
2 days 8 (13.3) 13 (19.7)
3 days 11 (18.3) 13 (19.7)
4 days 14 (23.3) 5 (7.6)
5 days 10 (16.7) 6 (9.1)
6 days 10 (16.7) 1 (1.5)
7 or more days 7 (11.7) 5 (7.6)
Median (range) 4 (2–8)* 2 (1–16)
Total number of in-patient days 265 199
*Po0.0005, Mann–Whitney U-test.
aIncludes duration of initial admission and after
readmission where appropriate.
Table 5 Resource utilisation
Intravenous
arm n¼60
Oral arm
n¼66
Approximate costs of febrile neutropenic episodes (d)
Hospitalisation 38690 29050
Antibiotics 11690 2060
Total 50380 31110
Mean, per episode 840 470
Approximate number of nursing hours ‘in direct patient contact’
Total 1258 733
Mean, per episode 21 11
Table 6 Multinational association for supportive care in cancer scoring
system for the proposed risk index for identifying low-risk febrile
neutropenic patients (Klastersky et al, 2000)
Characteristic Score
Burden of illness: no or mild symptoms
a 5
No hypotension 5
No chronic obstructive pulmonary disease 4
Solid tumour or no previous fungal infection 4
No dehydration 3
Burden of illness: moderate symptoms
a 3
Outpatient status 3
Age o 60 years 2
aPoints attributable to burden of illness are not cumulative. The maximum theoretical
score is therefore 26. The authors used a threshold of X21 points to define
‘low-risk’.
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lsince in most series of febrile neutropenia around two-thirds of
patient episodes fit into this category.
The success rate without modification of the initial antibiotic
regimen of the oral arm of this study was similar to the
intravenous arm, 84.8 and 90%, respectively. These success rates
are consistent with those of the largest open-label study
(Rubenstein et al, 1993; Talcott et al, 1994; Kern et al, 1999),
which has demonstrated equivalence of oral antibiotics compared
with intravenous treatment in the in-patient setting. In our study,
there was some evidence that clinicians were more confident of the
intravenous regimen than the oral regimen. Firstly, there was an
excess of failures in the oral arm due solely to persistent fever in
the absence of clinical deterioration or resistance (Table 3). In
addition, there was a greater number of patients in the intravenous
arm who remained as in-patients beyond 4 days than one might
have anticipated, given the 90% success rate of this arm. The
majority of these patients had not been discharged because they
did not fulfil the criteria for discharge of a rising neutrophil count.
However, we identified five episodes in which patients had
remained pyrexial for more than 72h without antibiotic modifica-
tion due to clinical well being. There were no such episodes in the
oral arm. Hence, the success rate of the intravenous arm may have
been somewhat overestimated.
More importantly, we encountered no significant problems with
safety of the oral antibiotics and early discharge strategy: only one
patient receiving oral antibiotics had significant clinical deteriora-
tion and this occurred within the initial 24-h mandatory
monitoring period. However, we acknowledge that given the
relatively small size of this study, there was limited power to detect
small but clinically important differences in safety. In addition, in
our study, all patients fulfilled strict entry criteria including good
history of compliance and supportive home environment with
continued contact by telephone with the specialist centre after
discharge and rapid access for readmission to the centre in the
event of deterioration. In view of this, our follow-up programme
was less stringent than recently published guidelines suggest (Feld
et al, 2002). Although there are presently no evidence-based
criteria for optimal monitoring of patients postdischarge, we
believe that more robust follow-up guidelines should be con-
sidered in the setting of less-specialised centres or multicentre
trials.
Perhaps a more useful outcome measure than the conventional
response to the initial antibiotic regimen is the success of the early
discharge policy, as judged by the low readmission rate. Only five
episodes (7.6%) required readmission, one of these for reasons
apparently unrelated to the neutropenic episode. We used the
criteria of clinical stability as judged by individual clinicians
together with patients’ symptomatic response to determine
whether patients were eligible for early hospital discharge. This
use of patients’ subjective response is supported by a study from
the MD Anderson Cancer Center (Elting et al, 2000). In this study,
data from episodes of febrile neutropenia included in previous
trials were examined to determine the value of various clinical
criteria in predicting the outcome of the episode, that is, whether
the episode resolved without antibiotic modification. The authors
found that adding subjective patient response to objective
measures of fever lysis substantially improved specificity of
prediction of overall success of an antibiotic regimen with little
loss of sensitivity.
The majority of patients admitted with complications of
chemotherapy are receiving palliative treatment. Thus, the shorter
duration of hospitalisation in the oral arm may be anticipated to
impact upon patients’ quality of life. Unfortunately, currently
available instruments designed for measuring quality of life
(Zigmond and Snaith, 1983; de Haes et al, 1990; Aaronson et al,
1993; Cella et al, 1993) are designed for comparison over weeks or
months. Therefore, measurements in febrile neutropenia, where
onset of infection and resolution of an episode may be only a few
days apart, are unlikely to be helpful. Accurate assessment of the
potential impact on patients’ quality of life of this approach to the
management of febrile neutropenia will require the development of
more sensitive instruments. However, patient acceptability is
perhaps a surrogate marker of quality of life. Thus by enabling
clinically eligible patients to be involved in discharge planning they
are able to make their own judgements about whether early
discharge or continued in-patient treatment would be preferable.
Of note is that while many patients expressed their preference for
early discharge, a minority chose to remain in hospital for
additional social and psychological support until the episode had
completely resolved. Hence, early discharge is not a preferred
option for all patients.
Toxicity of treatment is also an important end point and is also
likely to impact upon patients’ quality of life. In this study, toxicity
in the oral arm was generally mild and consisted of easily managed
nausea and diarrhoea. Only one patient required antibiotic
modification because of toxicity. Toxicity was less than was
reported in the two largest studies comparing oral and intravenous
regimens (Freifeld et al, 1999; Kern et al, 1999), a discrepancy
presumably partly attributable to under-reporting of adverse
events by patients after discharge.
Resource implications of different therapeutic strategies are
increasingly important in all healthcare systems. The major
financial burden of conventional treatment of neutropenic fever
is the cost of in-patient care, estimated to be between 58 and 78%
of the total cost. (Leese, 1993; Rubenstein et al, 1993; Dranitsaris
et al, 1995). In this study, the duration of hospital stay in the oral
arm was significantly shorter than in the intravenous arm with a
median in-patient stay of 2 days compared with 4 days. Overall,
this gave a saving of 66 days of hospital stay in the oral compared
with the intravenous arm. This is reflected in the comparison of
the costs of the two arms of the study. It should be noted that
the stay length in the intravenous arm is already shorter than
previous studies, which estimated a mean stay of 6.3 days
(Leese, 1993). This is because our ‘standard’ management guide-
lines already incorporate a policy of discharge when patients are
afebrile for 24h and with a rising neutrophil count, irrespective of
the absolute value (Marshall et al, 2000). While this approach
appears less stringent than published guidelines (Hughes et al,
2002), it represents a policy derived at a specialist centre with
considerable experience in the management of low-risk patients.
Hence, the savings in hospital admission days using oral
antibiotics with early discharge would be greater if compared with
more conventional management approaches. In addition, cost per
in-patient day varies greatly, both between and within countries.
Therefore, the potential savings of introducing this treatment
approach would be dependent on existing local policies and
circumstances.
The introduction of oral antibiotics and early hospital
discharge may have additional, though less easily quantifiable,
benefits with respect to nursing and pharmacy time. Oral therapy
clearly negates the requirement for care of intravenous cannulae as
well as aseptic reconstitution. Assessment using the GRASP
nursing management tool suggested that this treatment approach
might reduce number of nursing hours required in ‘direct patient
care’ by more than half.
In conclusion, our study suggests that oral antibiotics in
conjunction with early hospital discharge for patients who remain
stable after a 24h period of in-patient monitoring offers a feasible
and cost-effective alternative to conventional management of low-
risk neutropenic fever. However, we urge caution when applying
these findings outside the setting of a single specialist centre. We
also recognise that the power of this study to detect small but
clinically important differences in safety is limited. We therefore
believe that the results of this study should provide a platform for
larger trials to further evaluate the policy of oral antibiotics with
early discharge in the multicentre setting.
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